Department of Surgery, Mayo Clinic Florida, Jacksonville, Florida.
J Surg Oncol. 2014 Jun;109(7):633-8. doi: 10.1002/jso.23569. Epub 2014 Jan 24.
We sought to examine adherence to National Comprehensive Cancer Network guidelines for use of radiation therapy (RT) in patients with soft tissue sarcoma (STS) in the United States.
The surveillance, epidemiology, and end results cancer registry was queried to identify patients undergoing surgery for truncal and extremity STS from 2004 to 2009.
Of 5,075 patients, 50% received RT. Although routine RT is not recommended for Stage I patients, 25% still underwent RT. Even though routine RT is recommended for Stage II and III tumors, only 60% underwent RT. On multivariate analysis predictors of RT included age <50 years (OR 1.57, 95% CI 1.28-1.91), malignant fibrous histiocytoma histology (OR 1.47, 95% CI 1.3-1.92), T2 classification (OR 1.88, 95% CI 1.60-2.20), and G3 (OR 6.27, 95% CI 5.10-7.72). Patients with Stage III STS who received RT showed improved disease specific survival at 5 years compared to those who did not, 68% versus 46%, P <0.001.
Underuse of RT is seen for a significant proportion of patients undergoing treatment for STS in the United States. More effort needs to be directed towards compliance with appropriate treatment recommendations, perhaps by regionalizing sarcoma care or remote multidisciplinary tumor boards.
我们旨在研究美国软组织肉瘤(STS)患者接受放疗(RT)的依从性是否符合国家综合癌症网络(NCCN)指南。
通过监测、流行病学和最终结果癌症登记处,对 2004 年至 2009 年接受躯干和四肢 STS 手术的患者进行了检索。
在 5075 名患者中,有 50%接受了 RT。尽管Ⅰ期患者不推荐常规 RT,但仍有 25%的患者接受了 RT。尽管Ⅱ期和Ⅲ期肿瘤推荐常规 RT,但仅有 60%的患者接受了 RT。多因素分析显示,RT 的预测因素包括年龄<50 岁(OR 1.57,95%CI 1.28-1.91)、恶性纤维组织细胞瘤组织学(OR 1.47,95%CI 1.3-1.92)、T2 分类(OR 1.88,95%CI 1.60-2.20)和 G3(OR 6.27,95%CI 5.10-7.72)。接受 RT 的Ⅲ期 STS 患者 5 年疾病特异性生存率明显高于未接受 RT 的患者(68%比 46%,P<0.001)。
美国相当一部分接受 STS 治疗的患者 RT 应用不足。需要更加努力地遵守适当的治疗建议,例如通过区域化肉瘤治疗或远程多学科肿瘤委员会来实现。